

Contents

Contributors	xi	2.5 Medicinal Plant Production in China and India	32
Foreword	xiii	2.6 Supply, Demand, and Sustainability	34
Preface	xv	2.7 The Tea Value Chain	35
Acknowledgments	xvii	2.8 The Ginseng Value Chain	36
		2.9 Plant Metabolomics and Analytical Challenges	37
1. Quality Related Safety Issue-Evidence-Based Validation of Herbal Medicine Farm to Pharma	1	2.10 Discussion	39
PULOK K. MUKHERJEE, SHIV BAHADUR, SUSHIL K. CHAUDHARY, AMIT KAR, KAKALI MUKHERJEE		Acknowledgments	42
1.1 Health Care through Herbal Medicine	2	References	42
1.2 Integrated Approaches for Development of Herbal Medicine	2	List of Abbreviations	44
1.3 Use of Herbs in TM	4		
1.4 Globalization of TM	4	3. Traditional Herbal Medicine, Pharmacognosy, and Pharmacopoeial Standards: A Discussion at the Crossroads	45
1.5 TM Inspired Drug Discovery and Drug Development	6	ROY UPTON R.H.	
1.6 Issues for Quality Control and Quality Assurance of Herbal Medicine	7	3.1 Introduction	46
1.7 Marker Analysis and Standardization of Botanicals	9	3.2 Historical Perspectives on Traditional Herbal Medicine	47
1.8 Pharmacovigilance of Herbal Medicine	11	3.3 Modern Medicine—An American Case History	55
1.9 Safety Issues on Herbal Medicine-Cytochrome P450 Study	13	3.4 Traditional Herbal Medicines: Centuries of Empiricism	59
1.10 Herb-Drug Interactions	21	3.5 Traditional Medicine: Therapeutics, Definitions, and Orientations	61
1.11 System Biology and Metabolomics	22	3.6 Standard of Herbal Drugs in Early Pharmacopoeias	66
1.12 International Harmonization	24	3.7 Other Qualitative Factors Not Considered in Pharmacopoeias	76
1.13 Conclusion	24	3.8 Preventive Care and Self-Responsibility	79
Acknowledgments	25	3.9 Conclusion	80
References	25	References	81
List of abbreviations	28		
2. Value Chains of Herbal Medicines—Ethnopharmacological and Analytical Challenges in a Globalizing World	29	4. Taxonomy—An Irreplaceable Tool for Validation of Herbal Medicine	87
ANTHONY BOOKER, DEBORAH JOHNSTON, MICHAEL HEINRICH		RAINER W. BUSSMANN	
2.1 Introduction	29	4.1 Introduction	87
2.2 The Concept of Value Chains	30	4.2 Voucher Specimens	88
2.3 The Medicinal Plant Value Chains—Research Needs	30	4.3 Plant Identification	95
2.4 Medicinal Plant Value Chains in Asia	31	4.4 Label Requirements for Botanical Supplements and Other Materials in Trade	97
		4.5 The Problem of Lacking Vouchers and Incorrect Identification	97
		4.6 Problems with the Lack of Taxonomic Attention	97
		4.7 Conclusions	116
		References	117

5. Validation of Medicinal Herbs for Skin Aging	119	8.3 Development of Effective Antiviral Drugs	177
PULOK K. MUKHERJEE, SHIV BAHADUR, SUSHIL K. CHAUDHARY, RANJIT K. HARWANSI, NEELESH K. NEMA		8.4 Medicinal Plants as a Source of Antiviral Drugs: an Overview	177
5.1 Introduction	120	8.5 Methods for the Validation of Antiviral Activity of Plants	178
5.2 Consequences of Herbal Cosmetic	120	8.6 Future Prospects and Directions	196
5.3 Skin Aging	121	References	196
5.4 Factors Associated with Skin Aging	122	List of Abbreviations	200
5.5 Photoprotective Mechanism of Bioactive Molecules	124	9. Harmonization of Regulatory Requirements in Europe to Ensure Quality, Safety and Efficacy of Herbal Medicinal Products	201
5.6 Natural Bioactive Molecules against Skin Aging	128	WERNER KNÖSS	
5.7 Few Medicinal Plants Useful in Skin Aging	128	9.1 Introduction	201
5.8 Management of Skin Aging	141	9.2 HMPG: Establishment and Working Structure	202
5.9 Conclusion	143	9.3 Basic Legal Definitions and Access to the Market	203
Acknowledgments	143	9.4 Monographs and List Entries: Well-Established Use and Traditional Use	204
References	143	9.5 Procedure to Establish Monographs	205
List of Abbreviations	147	9.6 Usage and Acceptance of Monographs	206
6. Proangiogenic Potential of Medicinal Plants in Wound Healing	149	9.7 Guidance on Quality, Efficacy, and Safety: Coordination	213
DEEPAK KASOTE, AIJAZ AHMAD, ALVARO VILJOEN		9.8 Outlook	213
6.1 Introduction	149	Conflict of Interest	215
6.2 Phases of Wound Healing	150	References	216
6.3 Angiogenesis and Its Role in Wound Healing	151	List of Abbreviations	216
6.4 Plants with Proangiogenic Potential	152	10. Bioavailability of Herbal Products: Approach Toward Improved Pharmacokinetics	217
6.5 Conclusion	160	PULOK K. MUKHERJEE, RANJIT K. HARWANSI, SAUVIK BHATTACHARYYA	
References	161	10.1 Introduction	218
List of Abbreviations	164	10.2 Factors Affecting Bioavailability and Pharmacokinetics of Herbal Products	218
7. Pharmacovigilance: Tools in Establishing the Safety and Acceptability of the Natural Health Products—Clinical Evaluation	165	10.3 The Bioavailability and Pharmacokinetics of Some Herbs and Phytoconstituents	224
LUIGI GORI, FABIO FIRENZUOLI		10.4 Challenges in Developing a Herbal Formulation	230
7.1 Introduction	165	10.5 Novel Drug Delivery Technology for Herbal Formulation	231
7.2 Brief Historical Review	166	10.6 Phospholipid Complex of Herbs—Modification of Bioavailability and Efficacy	237
7.3 Adverse Reactions	166	10.7 Conclusion	241
7.4 Pharmacovigilance	167	Acknowledgment	241
7.5 Adverse Effects and Herbal Adverse Effects	167	References	241
7.6 Pharmacovigilance and Herbal Pharmacovigilance	168	List of Abbreviations	245
7.7 Toxicologicologist's Toolkits	170		
7.8 Conclusions	172		
References	172		
List of Abbreviations	174		
8. Validation of Antiviral Potential of Herbal Ethnomedicine	175		
DEBPRASAD CHATTOPADHYAY, DURBADAL OJHA, SUPRIYA MONDAL, DEBAYAN GOSWAMI			
8.1 Introduction	176		
8.2 Rationale for Antiviral Drug Development	176		

11. Good Quality and Clinical Practices for the Future Development of Herbal Medicines		14. Drugs and Drug Leads Based on Natural Products for Treatment and Prophylaxis of Malaria	
GAIL B. MAHADY	247	SØREN BRØGGER CHRISTENSEN	307
11.1 Introduction	247	14.1 Malaria	307
11.2 Quality Issues: Lack of GMP or Failure to Comply with cGMP Guidelines	249	14.2 Drug for Treatment of Malaria	309
11.3 Safety of HMs in the United States, Europe, and Asia	250	14.3 Malaria Prevention through Vector Control	314
11.4 Efficacy: The Importance of Randomized Controlled Clinical Trials	253	14.4 Evidence-based Use of Phytomedicines	314
11.5 Future Outlook for HMs	255	14.5 Conclusion	317
References	256	References	318
List of Abbreviations	258	15. Evaluation of Natural Products against Biofilm-Mediated Bacterial Resistance	321
12. Traditional Medicine-Inspired Evidence-Based Approaches to Drug Discovery		TUHINADRI SEN, SANMOY KARMAKAR, RATUL SARKAR	
BHUSHAN PATWARDHAN	259	15.1 Introduction	321
12.1 Introduction	259	15.2 Biofilm Formation	323
12.2 Ayurveda Inspiration	260	15.3 Mechanism for Resistance due to Biofilm	324
12.3 Reverse Pharmacology	262	15.4 Biofilm and Quorum Sensing	325
12.4 <i>Semecarpus anacardium</i> Case	262	15.5 Quorum Sensing as a Target for Antimicrobial Therapy	329
12.5 Formulation Discovery	263	15.6 Natural Products as a QS Inhibitor	331
12.6 Phytopharmaceuticals as Drugs	264	15.7 Synergy with the Natural Products and Conventional Antibiotics	332
12.7 Clinical Research	264	15.8 Conclusions	332
12.8 The Artrex Story	265	Acknowledgments	334
12.9 Formulations for Arthritis	265	References	334
12.10 Rasayana and Immunoadjuvants	266	List of Abbreviations	338
12.11 Discovery Approaches	268	16. Clinical Effects of Caraway, a Traditional Medicine for Weight Loss	339
12.12 Herb-Drug Interactions	268	MAHNAZ KAZEMIPOOR, GEOFFREY A. CORDELL	
12.13 Quality Control and Standardization	268	16.1 Introduction	339
12.14 Evidence-Based Ayurvedic Medicine	269	16.2 Materials and Methods	347
12.15 Conclusion	269	16.3 Results	348
References	269	16.4 Discussion	352
13. Evaluation of Bioactive Compounds as Acetylcholinesterase Inhibitors from Medicinal Plants	273	16.5 Conclusions	357
SANTANU BHADRA, MANOJ K. DALAI, JOYDEB CHANDA, PULOK K. MUKHERJEE		16.6 Summary	357
13.1 Introduction	274	Acknowledgment	357
13.2 Cholinergic Pathway	274	References	357
13.3 Cholinesterase Inhibitors for Learning and Memory	275	List of Abbreviations	362
13.4 Medicinal Plants for the Management of Cognitive Disorder	277	17. Challenges in Identification of Potential Phytotherapies from Contemporary Biomedical Literature	363
13.5 Phytoconstituents for the Management of Cognitive Disorder	283	INDRA NEIL SARKAR	
13.6 Conclusion	302	17.1 Description of Medicinal Uses of Plants	363
Acknowledgments	302	17.2 Biomedical Literature	364
References	302	17.3 Concept Recognition	365
List of Abbreviations	306	17.4 Identifying Potential Plant-Therapy Relationships	368
		17.5 Conclusion	369
		References	369
		List of Abbreviations	371

18. Botanicals as Medicinal Food and Their Effects against Obesity	373	21. Discovery and Development of Lead Compounds from Natural Sources Using Computational Approaches	455
KAKALI MUKHERJEE, RAJARSHI BISWAS, SUSHIL K. CHAUDHARY, PULOK K. MUKHERJEE		JOSÉ L. MEDINA-FRANCO	
18.1 Introduction	373	21.1 Introduction	455
18.2 Pathogenesis of Obesity and Management Strategies	374	21.2 NPs in Drug Discovery	457
18.3 Phytochemicals Useful against Metabolic Disorder	377	21.3 Chemoinformatic Analysis of Natural Products	457
18.4 Herb as Food Useful in Obesity Management	387	21.4 Molecular Databases Focused on NPs and NP Derivatives	462
18.5 Medicinal Plant for Treatment of Obesity	396	21.5 Virtual Screening and Target Fishing	464
18.6 Prospect of Phytochemicals, Foods and Botanicals in Obesity Management	397	21.6 NPs as Leads for Challenging and Emerging Targets	466
18.7 Conclusion	398	21.7 Uncovering Bioactivities of NPs of Dietary Origin	469
Acknowledgment	398	21.8 Concluding Remarks	470
References	398	Acknowledgments	470
List of Abbreviations	402	References	470
		List of Abbreviations	475
19. Applications of High Performance Liquid Chromatography in the Analysis of Herbal Products	405	22. Infrared Spectroscopic Technologies for the Quality Control of Herbal Medicines	477
SATYAJIT D. SARKER, LUTFUN NAHAR		CHRISTIAN HUCK	
19.1 Introduction	406	22.1 Introduction	477
19.2 High Performance Liquid Chromatography (HPLC)	406	22.2 Technical Principles	478
19.3 Herbal Products	410	22.3 IR Imaging Spectroscopy	480
19.4 Types of Analysis of Herbal Products	411	22.4 Chemometrics Including Data Preprocessing	483
19.5 Analysis of Herbal Products by High Performance Liquid Chromatography	414	22.5 Adv- and Disadvantages of NIR and Imaging Spectroscopy	484
19.6 Conclusions	423	22.6 Quantitative Analysis of Secondary Metabolites	484
References	423	22.7 Qualitative Analysis: Classification, Discrimination and/or Authentication	489
List of Abbreviations	425	22.8 IR Imaging Spectroscopy Studies	490
		22.9 Regulatory Issues	491
20. Ayurveda — Opportunities for Developing Safe and Effective Treatment Choices for the Future	427	Acknowledgments	491
PRATIP K. DEBNATH, SUBHADIP BANERJEE, PARIKSHIT DEBNATH, ACHINTYA MITRA, PULOK K. MUKHERJEE		References	491
20.1 Ayurveda the Science of Life	428	List of Abbreviations	493
20.2 Knowledge Base of Ancient India	432	23. Antimicrobial Secondary Metabolites—Extraction, Isolation, Identification, and Bioassay	495
20.3 <i>Dravyaguna</i> : Pharmacodynamic Classification of Herbs in Ayurveda	434	MUKHLESUR RAHMAN	
20.4 <i>Nidana Samprapti</i> : Disease Pathogenesis in Ayurveda	435	23.1 Introduction	495
20.5 <i>Panchakarma Therapy</i> : Personalized Detoxification and Rejuvenation Therapy	438	23.2 Extraction and Isolation of Metabolites for Antimicrobial Potentials	497
20.6 Ayurveda: Rediscovering Novel Therapies	442	23.3 Identification of Compounds	498
20.7 <i>Rasashastra</i> : The Mystery of Ancient Chemistry	446	23.4 Bioassay: Methods Commonly Used for the Screening of Antimicrobial Activity	500
20.8 Ayur-Pharmacoepidemiology	448	23.5 Antimicrobial Secondary Metabolites	502
20.9 Conclusion	450	23.6 Conclusion	509
References	451	References	510
		List of Abbreviations	512

**24. Uses of Herbals in Cardiac Diseases:
Priority of Evidence Over Belief**

SUBIR K. MAULIK, SANJAY K. BANERJEE

24.1 Introduction	515
24.2 Epidemiology of CVD	516
24.3 Herbal Drug versus Modern Medicine	516
24.4 Validation of Indian Medicinal Plants for Cardioprotection	516
24.5 Experimental Data Obtained from Indian Medicinal Plants for Cardiovascular Activity	517

24.6 Medicinal Plants Used for Cardiovascular Diseases Other than Indian Medicinal Plants	520
24.7 Data Obtained from Human Studies with Medicinal Plants for Cardiovascular Effects	520
24.8 Indian Initiatives	526
24.9 Conclusion	526
References	526
List of Abbreviations	529

Index	531
--------------	------------